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Objectives:  This  single-arm  multicenter  Phase  II study  investigated  the  efﬁcacy  and  safety  of  pemetrexed
(Pem)  and cisplatin  (Cis)  induction  chemotherapy  (CT)  followed  by full-dose  Pem-Cis  plus concurrent
radiotherapy  (RT)  in  patients  with  locally  advanced  non-squamous  NSCLC.
Materials  and methods:  Patients  with  unresectable  Stage  III  non-squamous  NSCLC  received  two  21-day
cycles  of  Pem  500  mg/m2 (vitamin/folic  acid  supplementation  and  dexamethasone  prophylaxis  per  Pem-
label)  +  Cis 75  mg/m2 on  Day  1. Eligible  patients  who  had  not  progressed  continued  with  2 further  cycles
of  full-dose  Pem-Cis  plus  concurrent  RT  (2 Gy/fraction,  5  days/week,  66  Gy  total).  Primary  endpoint  was
the  1-year  progression-free  survival  (PFS)  rate.
Results: Of  90  patients  enrolled  (all treated;  median  age  61 years,  male/female  57%/43%, ECOG  perfor-
mance  status  0/1  66%/34%,  adenocarcinoma  90%,  Stage  III  36%/62%),  75  (83%)  completed  induction  CT
and started  concurrent  CT +  RT.  64  (71%)  patients  received  all 4 CT cycles  and  an  RT  dose  ≥60  Gy.  The
1-year  PFS  rate was  51.3%  (95%CI:  42.0,  60.5).  Median  PFS  was  10.6  months  (95%CI:  8.6, 17.3),  median
OS  was  26.2  months  (95%CI:  16.7,  not  estimable).  One  patient  died  from  enteritis  (treatment-related)
during Cycle  4.  Four  patients  discontinued  due  to  treatment-related  adverse  events,  1 on  induction  CT
(renal  failure),  3 on  concurrent  CT + RT (1 hypoacusis,  2 acute  esophagitis).  During  induction  CT, 18.9%
of  patients  reported  Grade  3/4  CTCAEs,  only  neutropenia  (2.2%)  and  syncope  (2.2%)  were  reported  by  >1
patient.  During  concurrent  CT + RT,  41.3%  of  patients  reported  G3/4  CTCAEs,  mainly  esophagitis  (12.0%),
neutropenia  (10.7%),  and  leukopenia  (9.3%).
Conclusion:  In  this  study  of  Pe
median  PFS  was 10.6  months  
RT.
© 2015  The  Authors.  Pu
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. Introduction
Lung cancer remains the leading cause of cancer-related death
orldwide. Non-small-cell lung cancer (NSCLC) accounts for
pproximately 85% of all cases, and about 25% of these have
ocally advanced disease [1]. Concurrent chemo- and radiotherapy
RT + CT) seems to be superior to sequential treatment, with a sur-
ival advantage of approximately 6.6% at 3 years [2,3]. Therefore,
T + RT has been recommended as current standard of care for
atients with locally advanced, unresectable Stage III NSCLC [4].
owever, the optimal strategy remains undeﬁned, leading to a
ajor clinical challenge of distant control as no third-generation
gent can be given at full systemic dose when combined with tho-
acic radiation [5].
In 2 Phase-III-trials (Vokes study [5], Kim study [6]), patients
ith unresectable Stage III NSCLC received platinum-based CT
ith concurrent RT (planned dose 66 Gy), either with or with-
ut 2 preceding cycles of induction CT [5,6]. However, efﬁcacy
esults in both studies failed to show an advantage of the induc-
ion CT arm versus the comparator arm, and in the Vokes study
nduction CT was associated with increased toxicity [5,6]. Despite
hese results we believe that induction CT followed by concur-
ent chemoradiotherapy in a regimen slightly different from those
ssessed in the aforementioned Phase-III-studies, i.e. with full-
ose cisplatin (Cis), will provide beneﬁt in patients with advanced
SCLC.
The combination of Cis and full-dose pemetrexed (Pem-Cis) has
hown promising activity and tolerability in locally advanced unre-
ectable Stage III disease when combined with RT [7–9].
So far, pemetrexed (Pem) may  represent the only third-
eneration agent to be safely administered at full-dose in
ombination with Cis and RT, avoiding compromise on activ-
ty against distant disease while optimizing local control. In
his study, we evaluated induction therapy with Pem-Cis, a
tandard combination used in Stage IV non-squamous NSCLC
10].
Based on previous data, the current Phase-II-study was designed
o investigate efﬁcacy and safety of 2 cycles of Pem-Cis induction CT
ollowed by 2 cycles of full-dose Pem-Cis combined with concur-
ent RT in patients with locally advanced Stage III non-squamous
SCLC. Given the absence of any proven beneﬁt in favor of one spe-
iﬁc approach, we opted for an induction design considering it may
ffer some advantages: selection of suitable patients for local treat-
ent, and tumor volume reduction prior to RT in CT-responders
5,11].
. Materials and methods
.1. Study design
H3E-EW-S128 was a single-arm, multicenter, open-label, Phase-
I-study of 2 cycles of ﬁrst-line Pem-Cis induction CT (induction CT),
ollowed by 2 cycles of Pem-Cis with concurrent thoracic RT (con-
urrent CT + RT) in patients with locally advanced non-squamous
SCLC (Appendix Fig. A1). All patients were followed-up for ≥2
ears after start of induction CT.
The primary objective was to assess the 1-year progression-
ree survival (PFS) rate. Secondary outcomes included objective
umor response rate (ORR), overall survival (OS), safety, and tol-
rability. The study was approved by institutional review boards
nd conducted in accordance with the Declaration of Helsinki. All
atients had to provide written informed consent before participat-
ng in the study. The study was registered at www.clinicaltrials.gov
NCT01000480).r 88 (2015) 160–166 161
2.2. Patients
Men  and women  (≥18 years old) with unresectable, measur-
able (≥1 unidimensionally measurable lesion) Stage IIIA or Stage
IIIB non-squamous NSCLC, without malignant pleural/pericardial
effusions (AJCC Version 6) [12] were recruited between October
2009 and July 2011 at 21 sites in France, Germany, Italy, and Spain.
Patients with an Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) of 0 or 1, and no prior systemic therapy for
lung cancer were eligible. Prior non-thoracic RT limited to <25% of
bone marrow was  allowed if completed 30 days before enrolment.
Adequate bone-marrow reserve, adequate hepatic, renal, and pul-
monary function (forced expiratory volume in 1 s [FEV1] >50% of
predicted normal value, carbon monoxide lung-diffusing capacity
[DLCO] >40% of predicted normal value), and a total lung volume
receiving at least 20 Gy (V20) ≤35% were mandatory.
2.3. Treatment
Chemotherapy:  Patients received 2 cycles of induction CT with
500 mg/m2 Pem infused over approximately 10 min, followed by
75 mg/m2 Cis infused starting approximately 30 min  after dosing
of Pem, given every 21 days (q3w, Day 1 of each cycle). All patients
received prophylactic oral dexamethasone, and folic acid and vita-
min  B12 supplementation as per Pem-label. Cis was  administered
according to local practice. After 2 cycles of induction CT, patients
with documented radiographic evidence of complete response
(CR), partial response (PR), or stable disease (SD) (RECIST 1.0) [13]
were eligible to start concurrent CT + RT if they had an ECOG PS
of 0 or 1, total lung V20 ≤35% and no residual neurological toxic-
ity ≥grade (G) 2. Eligible patients received 2 additional cycles of
full-dose Pem-Cis CT (as described above) with concurrent RT.
Radiotherapy: Thoracic RT started 22–36 days after the second
infusion of Pem-Cis induction CT. Patients received 3-dimensional
conformal RT at 2 Gy daily fractions (Monday through Friday), up
to the total planned dose of 66 Gy. Gross tumor volume (GTV), clin-
ical target volume (CTV), and planning target volume (PTV) were
deﬁned based on a mandatory computed tomography simulation
scan performed after 2 cycles of induction CT, with patient in treat-
ment position using speciﬁc devices. Treated volumes included the
GTV or both primary tumor and nodal diseases, without elective
nodal irradiation (CTV equal to GTV). Margins from CTV to PTV were
depending on individual centers’ protocols, but generally in the
range of 10–15 mm.  According to each center’s protocol, respira-
tory gating could be used. Linear accelerators operating at a beam
energy of ≥6 MV  were to be used. If therapy interruption for ≤1
week was  necessary, irradiation was then resumed and completed
to the prescribed dose. If a consecutive interruption of RT >7 days
was required, the patient was  discontinued from study treatment
and treated at the discretion of the investigator.
2.4. Outcomes and assessments
PFS was deﬁned as the time from enrolment to the ﬁrst date
of objectively determined PD or death from any cause. OS was
deﬁned as time from enrolment to the date of death from any
cause. A CT and an initial positron emission tomography (PET) scan
were mandatory for tumor staging. Computed tomography scans
(including spiral computed tomography) were used for response
assessment. Tumor was  assessed at baseline, at the end of Cycle 2,
and 6–8 weeks after the last RT dose (in patients eligible for con-
current CT + RT). The follow-up was  every 3 months through the
ﬁrst year and every 6 months the second year. ORR was  deﬁned as
the proportion of patients with conﬁrmed CR or PR according to
RECIST criteria at the end of treatment; disease control rate (DCR)
was deﬁned as the proportion of patients with conﬁrmed CR or PR
1  Cancer 88 (2015) 160–166
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15 (1 6.7%) di scon tinued
6 progressive disease
4 protoc ol entr y criter ia not met
2 adverse event
1 physician decision
1 patient decision
1 lost to follow-up
113  pat ients 
scree ned
75 (83 .3%) 
started concurrent CT + RT
22 did  no t meet entry crit eria
1 did no t sign cons ent 
11 (1 2.2%) di scon tinu ed
4 ad verse  even t
3 patien t decis ion
2 prot ocol viol ati on
1 ph ysic ian  decis ion
1 dea th (to xic ity: en teritis)
64 (71.1%) 
90 (100.0%) 
starte d induct ion  CT
Of these, 19 patients (25.3%) experienced local disease progression
(14 [18.7%] within the radiation ﬁeld; 5 [6.7%] within the thorax
but outside the radiation ﬁeld) and 22 (29.3%) developed distant
metastases.
Table 1
Baseline characteristics.
Parameter Patients enrolled (N = 90)
Age [years], median (range) 61.4 (42.3, 80.5)
Sex, n (%)
Male 51 (56.7)
Female 39 (43.3)
Race, n (%)
Caucasian 90 (100)
Smoker, n (%)
Current smoker 28 (31.1)
Ex-smoker 55 (61.1)
Never smoked 7 (7.8)
ECOG performance status, n (%)
0 59 (65.6)
1 31 (34.4)
Initial pathological diagnosis, n (%)
Adenocarcinoma 81 (90.0)
Other histologiesa 9 (10.0)
Stage of disease (AJCC Version 6), n (%)
Stage IIIA 32 (35.6)
Stage IIIB 56 (62.2)
Stage IVb 2 (2.2)
Prior radiotherapy, n (%) 1 (1.1)
FEV1 [% predicted], median (range)c 77.5 (41.0, 141.0)
AJCC = American Joint Committee on Cancer Staging Manual; CT = chemotherapy;
ECOG = Eastern Cooperative Oncology Group; FEV1 = forced expiratory volume in
1  min; N = total number of patients; n = number of patients; NOS = not otherwise
speciﬁed; NSCLC = non-small cell lung cancer; RT = radiotherapy.
a Other histologies included large cell lung carcinoma (7 patients), NSCLC, poorly62 P. Garrido et al. / Lung
r with SD. Adverse event (AE) data were collected at each visit up
o 30 days after the last dose of study treatment (including the last
T dose); treatment-related serious AE data were collected until the
nd of the 2-year follow-up period. Laboratory data were collected
p to the end of study treatment.
.5. Statistical analysis
Sample size: A minimum of 53 events (PD or death) was required
o achieve 90% power to demonstrate an improvement of the 1-year
FS rate from 45% (historical data) [14] to 60% at a 2-sided alpha-
evel of 5%. Assuming an accrual period of 18 months, a minimum
ollow-up of 1 year for all patients and a 10% drop-out rate, 88
atients were planned to be enrolled.
Analysis populations: Efﬁcacy analyses were based on all enrolled
atients. Safety analyses included all patients who received ≥1
ose of study treatment. Additional efﬁcacy analyses were based
n those patients starting concurrent CT + RT.
Primary analysis: The maximum-likelihood estimates for PFS
nd the appropriate 95% conﬁdence intervals (CIs) were calculated
ased on exponential distribution, using the asymptotic normality
f ln(), where  is the exponential parameter [15]. If the lower con-
dence limit of the 1-year PFS rate was >0.45, the null-hypothesis
ould be rejected. As a supportive analysis, the 1-year PFS rate was
stimated using Kaplan–Meier techniques [16]. PFS was censored
t the date of the last objective progression-free assessment prior
o any systemic post-discontinuation anti-cancer therapy.
Secondary analyses: median OS (mOS), median PFS (mPFS), and
S rates were estimated using Kaplan–Meier techniques. ORR
nd DCR were presented including exact binomial 95%CIs [17].
ncidence and maximum G of hematologic and non-hematologic
oxicities were evaluated based on reported treatment-emergent
Es, using National Cancer Institute Common-Toxicity-Criteria AE
erminology (Version 3.0) [18].
Post-hoc analyses: Tumor response was additionally sum-
arized based on tumor assessments performed prior to
ost-discontinuation surgery. Duration of CR, deﬁned as time from
rst date of objectively determined CR to ﬁrst date of objectively
etermined PD or death from any cause, was analyzed descrip-
ively.
Statistical Analysis Software version 9.2 was used (SAS®, SAS
nstitute Inc., Cary, USA).
. Results
.1. Disposition and patient characteristics
Of 113 patients screened, 90 patients started induction CT and
5 (83.3%) received concurrent CT + RT treatment (Fig. 1). Of these,
4 patients (71.1%) completed 4 cycles of full-dose CT with an RT
ose of ≥60 Gy and therefore were considered to have completed
he planned treatment.
Patients’ median age was 61.4 years; 56.7% were male; 90.0%
ad adenocarcinoma, and 62.2% had Stage IIIB disease (Table 1).
.2. Dose and exposure
Eighty-ﬁve patients (94.4%) completed induction CT and 72
80.0%) completed all 4 CT cycles (Table 2). Overall, patients
eceived a median of 4 cycles of Pem and Cis with relative dose
ntensities >90% throughout induction CT and concurrent CT + RT
hases (Appendix Table A1).
Most patients received the planned radiation dose of 66 Gy (65
f 90 patients, 72.2%) (Table 2), 4 patients received between 60 and
6 Gy, whereas 6 patients received <60 Gy.complet ed trea tment
Fig. 1. Patient disposition. CT = chemotherapy; RT = radiotherapy.
3.3. Progression-free and overall survival
With a 1-year PFS rate of 51.3% (95%CI: 42.0, 60.5), the study did
not meet the primary endpoint. mPFS was 10.6 months (95%CI: 8.6,
17.3) (Fig. 2A). A total of 41 patients (54.7%) had documented PD.differentiated (1 patient), and NSCLS, NOS (1 patient).
b Two  patients with Stage IV disease were enrolled (major protocol deviation).
Both patients were discontinued from the study before starting the concurrent
CT  + RT period.
c Was  not assessed in 2 patients.
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Table  2
Chemotherapy exposure and delivered radiotherapy (N = 90).
Chemotherapy
Parameter Pemetrexed Cisplatin
Number of cycles received
Median (range) 4.0 (1, 4) 4.0 (1, 4)
Completed 2 cycles of induction CT, n (%) 85 (94.4)
Completed 4 cycles of CT, n (%) 72 (80.0)a
Relative dose intensity [%], median (range)b
Induction CT period 90.4 (64, 105) 91.6 (64, 105)
Concurrent CT + RT period 98.8 (0c, 132) 97.6 (0c, 132)
Overall treatment period 92.2 (53, 103) 92.3 (53, 105)
Radiotherapy
Received at least 1 dose of RT, n (%) 75 (83.3)
Total RT dose received [Gy]
Median (range) 66 (18, 66)
Full  dose (66 Gy), n (%) 65 (72.2)
60  to <66 Gy, n (%) 4 (4.4)
<60 Gy, n (%) 6 (6.7)d
Number of fractions delivered, median (range) 33 (9, 33)
Duration of RT [days], median (range) 46 (13, 63)
Total lung mean dose [Gy], median (range), (N = 68) 17.8 (1, 68)
Total lung V20 [%], median (range), (N = 65) 28 (14, 41)
RT  delivery method, n (%)
3-dimensional conformal 69 (92.0)
4-dimensional conformal 6 (8.0)
CT = chemotherapy; N = number of patients; RT = radiotherapy; V20 = volume to
receive at least 20 Gy.
a 64 of 72 patients also received ≥60 Gy of RT (“completed treatment”).
b Relative dose intensity calculated as (actual mean dose/planned mean
dose)*100%.
c One patient who  started the concurrent CT + RT period received no CT in Cycles
3  and 4, but full-dose RT (66 Gy).
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Fig. 2. Progression-free (A) and overall (B) survival. CI = conﬁdence interval; N = total
number of patients; n.e. = not estimable; OS = overall survival; PFS = progression-
free survival; PD = progressive disease. (a) Maximum likelihood estimate. (b)
Kaplan–Meier estimate.
Table 3
Tumor response.
Parameter Patients starting
induction CTa (N = 90)
Patients starting
concurrent CT + RTa
(N = 75)
Best overall response, n (%)
Complete response b 9 (10.0) 9 (12.0)
Partial response 45 (50.0) 45 (60.0)
Stable disease 16 (17.8) 16 (21.3)
Progressive disease 12 (13.3) 4 (5.3)
Unknown/not evaluable c 8 (8.9) 1 (1.3)
ORR (CR + PR), n (%) 54 (60.0) 54 (72.0)
95%CI 49.1, 70.2 60.4, 81.8
DCR (CR + PR + SD), n (%) 70 (77.8) 70 (93.3)
95%CI 67.8, 85.9 85.1, 97.8
CI = conﬁdence interval; CT = chemotherapy; CR = complete response; DCR = disease
control rate; N = total number of patients; n = number of patients with response;
ORR = overall response rate; PR = partial response; RT = radiotherapy; SD = stable dis-
ease.
a Best overall response is based on all tumor assessments starting from induction
CT.
b The 9 CRs lasted between 3.8 and 19.6 months; all CR patients were disease-free
at  the last follow-up visit, i.e. after ≥2 years of follow-up.1 patient received 18 Gy in 9 fractions, 2 patients received 38 Gy in 19 fractions,
 patient received 48 Gy in 24 fractions, 1 patient received 50 Gy in 25 fractions, and
 patient received 52 Gy in 26 fractions.
After a median follow-up of 25.4 months (range 0.1–35.4
onths), the OS analysis was performed at 50% maturity. mOS  was
6.2 months (95%CI: 16.7, not estimable); the 2-year OS rate was
4.2% (95%CI: 43.2, 64.0) (Fig. 2B).
For the 75 patients starting concurrent CT + RT, mPFS was  12.5
onths (95% CI: 9.6, 19.0), and mOS  was 30.0 months (95%CI: 21.3,
ot estimable), with a 2-year OS rate of 60.4% (95%CI: 48.3, 70.6).
.4. Post-discontinuation therapy
Although all patients had unresectable tumors at baseline 15
atients (16.7%) were able to undergo surgery after discontinuation
f study treatment, and 6 patients had no measurable lesion after
urgery. In addition, there were 3 patients with CR after concurrent
T + RT (Table 3).
Twenty-four patients (26.7%) received thoracic RT, and
3 (36.7%) received systemic therapy. Docetaxel (15 patients,
6.7%) and erlotinib (11 patients, 12.2%) were the agents used most
requently (Appendix Table A2).
.5. Safety
Induction CT:  The only hematologic G3/4 toxicity reported dur-
ng induction CT was neutropenia in 2 patients (1 G3, 1 G4; 2.2%)
Fig. 3A). The only G4 non-hematologic toxicity was  hyponatremia;
he only G3 non-hematologic toxicity reported in >1 patient was
yncope (Appendix Table A3). Most non-hematologic toxicities
ere of G1/2. Two patients discontinued treatment due to non-
erious AEs associated with renal failure.
c Patients who discontinued study treatment before entering the concurrent
CT  + RT period but not due to progression were considered to have a response of
non-evaluable to whole treatment.
164 P. Garrido et al. / Lung Cancer 88 (2015) 160–166
Fig. 3. Toxicities by maximum CTCAE grade. (A) Hematologic toxicities during induction CT and concurrent CT+RT period. (B) Selected non-hematologic toxicities (adverse
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T  = radiotherapy. (a) CTCAE Version 3.0. (b) Mucositis: all CTCAE terms with the w
Concurrent CT + RT:  Neutropenia and leukopenia were the most
requent hematologic toxicities (Fig. 3A). 10.7% of 75 patients had
3/4 neutropenia (12.0% G1/2); 1 patient experienced G3 febrile
eutropenia. 9.3% of 75 patients had G3/4 leukopenia (13.3% G1/2).
sophagitis was the main non-hematologic toxicity during concur-
ent CT + RT (12.0% G3/4, 41.3% G1/2; Fig. 3B), but only 1 patient
xperienced G4 esophagitis (Fig. 3B). One patient died from study-
rug related enteritis during Cycle 4. No other G4 non-hematologic
oxicities were reported. Dysphagia, nausea, and fatigue, mainly G1
nd G2, were the only other non-hematologic toxicities reported by
20% of patients (Appendix Table A4). Four patients discontinued
ue to AEs: 2 because of esophagitis (serious, treatment-related),
 because of hypoacusis (serious, treatment-related), and 1 because
f acute pneumonia (serious, non-related).
Acute hematologic and non-hematologic toxicities reported
hroughout the complete 4 cycle treatment period are provided in
ppendix Fig. A2 and Appendix Table A5. Two patients reported late
tage AEs related to radiation (1 G3 pneumonitis starting 7 months
fter the last radiation; 1 G2 pneumonitis starting 1.5 months after
he last radiation).
. Discussion
This single-arm study in 90 patients with locally advanced
on-squamous NSCLC evaluated 2 cycles of Pem-Cis induction
T followed by 2 cycles of full-dose Pem-Cis with full-dose
66 Gy) concurrent RT. The majority of patients (71.1%) received
 cycles of full-dose Pem-Cis and the planned RT dose. Only 8%
f patients starting concurrent CT + RT received a suboptimal radi-
tion dose (<60 Gy). In another recent Phase-II-study by Garrido
t al. [19] in Stage III NSCLC assessing non-platinum induction or
onsolidation CT added to concurrent CT + RT (60 Gy), a larger per-
entage of patients (20% [consolidation arm]; 12% [induction arm])
eceived suboptimal radiation doses. Cis-based regimens have been
tudied most extensively, and are therefore recommended by = common terminology criteria for adverse events; N = total number of patients;
ucositis” combined.
current European Society for Medical Oncology (ESMO)  guidelines
for concurrent use with RT [4].
In the current study, Pem-Cis induction followed by full-dose
Pem-Cis CT with concurrent RT was  associated with a mPFS of
10.6 months (1-year PFS rate 51.3%), and a mOS of 26.2 months.
These data are within the range seen in a previous Phase-II-study,
in which patients received 2 cycles of Cis-based induction CT com-
bined with docetaxel, followed by concurrent oral vinorelbine plus
Cis (Vin-Cis) with RT (planned dose of 66 Gy) [11]. Similar results
with Cis-based induction CT followed by Vin-Cis with concurrent
RT (66 Gy) were reported by Fournel et al. [14], with mPFS of 11.5
months and mOS  of 19.3 months.
Results are also available from 2 Phase-III-studies: in the Vokes
study [5], the paclitaxel plus carboplatin (Pac-Carbo; 7 weekly
cycles) induction CT arm (followed by Pac-Carbo with concurrent
radiation at 66 Gy) achieved a mPFS of 8 months and a mOS  of 14
months [5]; in the Kim study [6], the induction CT (two 21-day
cycles of gemcitabine and cisplatin) arm (followed by 6 cycles of
weekly paclitaxel 50 mg/m2 and cisplatin 20 mg/m2 with concur-
rent radiation at 66 Gy) achieved a mPFS of 7.5 months and a mOS
of 12.6 months.
However, both studies failed to demonstrate a survival advan-
tage for induction chemoradiotherapy compared to chemoradio-
therapy alone, with mPFS and mOS  in comparator arms of 7 and
12 months in the Vokes study [5], and 11.6 and 18.2 months in the
Kim study [6], respectively. In the Vokes study [5], this was possi-
bly due to carboplatin being used in the induction and concurrent
treatment regimens instead of cisplatin. In the Kim study [6], it may
possibly be due to the low dose of cisplatin (20 mg/m2) used dur-
ing concurrent chemoradiotherapy. Thus, there was no compelling
evidence suggesting that the evaluated regimen with Pem and full-
dose Cis cannot provide beneﬁt in patients with locally advanced
NSCLC.
The toxicity proﬁle during Pem-Cis induction CT was similar
to the known proﬁle from Phase-III-studies evaluating Pem-Cis in
advanced non-squamous NSCLC [10,20]. The only G3 hematologic
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oxicity reported during induction CT was neutropenia (2 patients),
he only G3/4 non-hematologic toxicities reported were hypona-
remia and syncope (1 patient each).
Toxicity was also manageable during the concurrent Pem-
is with RT phase. G3/4 hematologic toxicity was in the range
bserved in other induction CT with concurrent CT + RT regimen
n Phase-II-trials. During the concurrent phase, G3/4 neutrope-
ia occurred in 10.7% of patients (compared with 4–10.5% for
in-Cis or docetaxel and carboplatin [Doce-Carbo]), and G3/4
eukopenia in 9.3% of patients (11% for Doce-Carbo) [11,19].
ess than 15% of patients reported G3/4 acute esophagitis (12%)
nd/or dysphagia (1.3%) (compared with 5.3% acute esophagi-
is/dysphagia for Vin-Cis, and 15% for Doce-Carbo) [11,19]. No
3/4 dyspnea was reported, and 2.7% of patients had G3/4 acute
neumonitis (0–2% for Vin-Cis or Doce-Carbo) [11,19]. Higher
3/4 toxicity rates were reported in the induction CT arm of
he Vokes Phase-III-study (neutropenia 31%, leukopenia 44%,
cute esophagitis 36%, dyspnea 19%, acute pneumonitis 10%)
5].
Support for the manageable toxicity proﬁle of Pem-Cis when
sed concurrently with radiation comes from interim safety
ata during the concurrent CT + RT period of the Phase-III-study
ROCLAIM [21]. Here, some toxicities (neutropenia, leukopenia,
neumonia) were seen signiﬁcantly less frequently with Pem-Cis
han with etoposide-Cis, and consistent with our study, the most
requent G3/4 toxicities in the Pem-Cis arm were neutropenia
18.4%), leukopenia (15.5%), and esophagitis (14.8%).
Additional safety data speciﬁcally for Pem-Cis during concur-
ent CT + RT are available from Phase-I/II-studies [8,22]. Despite
imited comparability with the current study due to different
esigns (e.g. induction CT followed by CT + RT versus CT + RT fol-
owed by consolidation CT), safety proﬁles are generally consistent
cross these studies. In the most recent 2-arm Phase-II-study
y Choy et al. [8], patients received 3 cycles of concurrent
T + RT with either Pem-Cis or Pem-Carbo plus a radiation
ose of 64–68 Gy, followed by 3 cycles of Pem consolidation
T. In the Choy study, 13.5% of patients in the Pem-Cis arm
eported treatment-related G3/4 neutropenia (Pem-Carbo arm
1.7%), compared with 8.9% of patients in the overall period
i.e. induction plus concurrent phase) of our study, and 7.7%
eported treatment-related G3/4 leukopenia (Pem-Carbo 10.9%),
ompared with 7.8% in our study. Only 1 patient had G4 esophagi-
is (3.8% G3); no other G4 non-hematologic treatment-related
oxicities were observed with Pem-Cis or Pem-Carbo. Dehydra-
ion was the most frequent G3 toxicity (Pem-Cis 9.6%, Pem-Carbo
.5%) [8]. In the single-arm study by Brade et al. [22], patients
ith unresectable Stage III NSCLC received 2cycles of Pem-Cis
lus a target RT dose of 61–66 Gy, followed by 2 cycles of Pem-
is consolidation CT. G3/4 neutropenia was reported by 38.5%
f patients, non-hematologic toxicities were manageable, and
on-hematologic G3/4 toxicities included only single cases of
sophagitis and pneumonitis, and 2 cases of late-stage esophageal
tenosis.
. Conclusions
The current study was limited by its non-comparative design,
lthough the sample size (90 patients) was substantial for a single-
rm Phase-II-study [23]. The results provide clinically relevant
nsights on Pem-Cis induction CT followed by full-dose Pem-Cis
T with concurrent RT. Previously published data support our
esults, suggesting that the toxicity associated with this regi-
en is manageable in patients with unresectable Stage-III NSCLC
ho are considered clinically ﬁt for concurrent chemoradiother-
py.r 88 (2015) 160–166 165
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